It involves the provision of AI, imaging and radiotherapy equipment and associated products and diagnostic imaging to public and private sector organisations.
The framework is run by Shared Business Services (SBS) on behalf of NHS organisations and enables NHS customers to directly procure equipment related to AI imaging, including Bleepa’s AI module. It has an estimated overall value of up to GBP360mln which lasts until 2025.
The AIM-listed group has developed an AI module for the Bleepa communication platform that allows clinical users to use third-party AI tools for the interpretation of medical imaging studies such as X-rays, CT scans and MRIs.
The AI module has already been configured to deploy the AI tools of Feedback’s commercial partners Qure.ai and Axial 3D.
The Bleepa AI module will allow NHS Bleepa customers to engage with AI tools of their choosing.
Bleepa is a mobile platform so these AI tools can be used in any setting, while usually they are confined to desktop PCs within hospitals.
The framework will allow NHS organisations to buy the Bleepa AI solution as a platform for AI tool deployment, with Feedback charging the AI companies a deployment fee through the platform.
“Clinicians do not want multiple apps on their devices and there is a clear role for a single platform that facilitates the deployment of multiple AI tools,” said Feedback’s chief executive Dr Tom Oakley.
“As a mobile first solution, that additionally facilitates patient pathways and clinical case discussion, Bleepa is the perfect deployment platform for AI tools, we can put the latest AI technology literally into the hands of clinicians, through their own devices, in any internet connected location, allowing truly on-the-go access to the best available diagnostic support tools and point-of-care deployment of AI technology in even more care settings.”